Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Luke Miels
Pharma
GSK reports blockbuster sales for Arexvy in RSV race vs. Pfizer
GSK's RSV shot Arexvy generated $1.5 billion in sales in 2023, compared to $890 million for Pfizer's Abrysvo. But GSK says the battle has just begun.
Kevin Dunleavy
Jan 31, 2024 9:50am
FDA approves GSK's Jakafi challenger in blood cancer
Sep 15, 2023 4:16pm
GSK's RSV vaccine pegged for blockbuster sales
Apr 26, 2023 10:26am
GSK strikes antifungal deal as deadly pathogen raises alarm
Mar 30, 2023 11:16am
JPM: GSK's Miels talks RSV and mRNA vaccines, oncology setbacks
Jan 11, 2023 5:45pm
Chris Sheldon is clear to join GSK from AZ next month
Oct 12, 2022 9:25am